Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.

Abstract: The present invention relates to a novel delivery system for delivering therapeutic agents into living cells, and more particularly, to novel chemical moieties that are designed capable of targeting and/or penetrating cells or other targets of interest and further capable of binding therapeutic agents to be delivered to these cells, and to delivery systems containing same.

Abstract: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and uses of the compound, particularly in antisense therapy.

Abstract: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and uses of the compound, particularly in antisense therapy.

Abstract: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and uses of the compound, particularly in antisense therapy.

Abstract: A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Novel conjugates of these oligomeric compounds and biologically active moieties, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically active substances to a desired target are further disclosed. Processes of preparing the conjugates and the oligomeric compounds and novel intermediates designed for and used in these processes are also disclosed.

Abstract: A novel class of oligomeric compounds designed for forming conjugates with biologically active substances and delivering these substances to a desired bodily target are disclosed. Novel conjugates of these oligomeric compounds and biologically active moieties, pharmaceutical compositions containing such conjugates, and uses thereof as delivery systems for delivering the biologically active substances to a desired target are further disclosed. Processes of preparing the conjugates and the oligomeric compounds and novel intermediates designed for and used in these processes are also disclosed.

Abstract: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and uses of the compound, particularly in antisense therapy.

Abstract: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and rises of the compound, particularly in antisense therapy.

Abstract: A compound which comprises a backbone having a plurality of chiral carbon atoms, the backbone bearing a plurality of ligands each being individually bound to a chiral carbon atom of the plurality of chiral carbon atoms, the ligands including one or more pair(s) of adjacent ligands each containing a moiety selected from the group consisting of a naturally occurring nucleobase and a nucleobase binding group, wherein moieties of the one or more pair(s) are directly linked to one another via a linker chain; building blocks for synthesizing the compound; and rises of the compound, particularly in antisense therapy.

Abstract: A compound comprising a poly(ether-thioether), poly(ether-sulfoxide) or poly(ether-sulfone) backbone bearing a plurality of ligands that are individually bound to chiral carbon atoms located within the backbone, at least one of the ligands including a moiety such as a naturally occurring nucleobase, a nucleobase binding group or a DNA interchelator; a process of synthesizing the compound, monomers to be used in this process and their synthesis process and processes for using the compound in biochemistry and medicine.

Abstract: A compound of a general structure: D—B—M wherein: B is selected from the group consisting of derivatives of naturally occurring nitrogenous bases having a C—H group at positions 5 or 8, and derivatives of nitrogenous base-analogs having a C—H group at positions 5 or 8; D is at least one derivatizing group, including hydrogen; and M is a maleimide derivative.

Abstract: This invention relates to a process for amplifying and detecting any desired specific nucleic acid sequence that exists in a nucleic acid or mixture thereof. The process comprises treating single strand RNA or separated complementary strands of DNA target with a molar excess of oligonucleotide complement pairs in which these oligonucleotide complement pairs have sequences complementary to the target, under hybridizing conditions. In one embodiment, the oligonucleotide complement pairs may have a gap of one or more bases which may be repaired (filled) by enzymes. The oligonucleotide complement pairs are joined together, forming joined, oligonucleotide product. The target/joined product hybrid nucleic acids are then denatured to single strands again, at which point both the target and the joined products can form hybrids with new oligonucleotide complement pairs. The steps of the reaction may be carried out stepwise or simultaneously and can be repeated as often as desired.

Abstract: A compound comprising a polyether backbone bearing a plurality of ligands that are individually bound to chiral carbon atoms located within said backbone, at least one of said ligands including a moiety selected from the group consisting of a naturally occurring nucleobase, a nucleobase binding group and a DNA intercalator; a process of synthesizing the compound, monomers to be used in this process and their synthesis process and processes for using the compound in biochemistry and medicine.

Abstract: The present invention is directed to a method of amplifying and detecting single or double stranded target nucleic acid molecules. Amplification of the target nucleic acid molecule is accomplished by using at least two chemically modified oligonucleotide probes per target nucleic acid molecule to form a joined oligonucleotide product. Each oligonucleotide probe is comprised of a long and short sequence. The long sequence of each probe hybridizes to adjacent regions of the target nucleic acid molecule. The short sequences of each probe hybridize to each other. Chemical functionality groups attached to the short sequences of each oligonucleotide probe covalently combine linking the probes to form a joined oligonucleotide product. The joined oligonucleotide product is formed without the use of enzymes.The reactivity of the chemical functionality groups on each probe is target dependent.

Abstract: The present invention and kits are directed to a method of amplifying and detecting single or double-stranded target nucleic acid molecules in a test sample. Amplification is accomplished through the use of a minimum of two oligonucleotide probe complement pairs, wherein members oligonucleotide probes from both pair of oligonucleotide probe complement pairs form a minimum of two oligonucleotide probe pairs, at least one of which is complementary to a given portion of a target nucleic acid sequence which act as template. One of the oligonucleotide probes of each oligonucleotide probe pair have an additional protecting sequence which is not complementary to the target sequence. These additional protecting sequences are preferably complementary to each other. Chemical functionality groups attached to the oligonucleotide probes covalently combine the probes to form a joined oligonucleotide product. The joined oligonucleotide product is formed without the use of enzymes.

Abstract: A method for amplifying a signal during the detection of target nucleic acid molecules utilizes a primary oligonucleotide probe that binds to a bridging nucleic acid molecule. The bridging molecule hybridizes to a first developer nucleic acid molecule. Each first developer molecule comprises: (a) a first branch having a sequence of at least two different nucleotides and at least six total nucleotides complementary to a sequence of a first branch of a second developer molecule; (b) a second branch comprising a sequence of at least two different nucleotides and at least six total nucleotides complementary to a sequence of a second branch of the second developer molecule; and (c) a detectable label.

Abstract: A composition of the formula: ##STR1## wherein X is lower alkyl, and Z is an amino acid a peptide residue or a good leaving group, the composition is adaptable as a blocking or protecting group for an amine composition useful in peptide synthesis and a method of protecting an amino group of an organic molecule during a reaction which modifies a portion of the molecule other than the protected amino group.